Carvedilol targets β-arrestins to rewire innate immunity and improve oncolytic adenoviral therapy

Oncolytic viruses are being tested in clinical trials, including in women with ovarian cancer. We use a drug-repurposing approach to identify existing drugs that enhance the activity of oncolytic adenoviruses. This reveals that carvedilol, a β-arrestin-biased β-blocker, synergises with both wild-typ...

Descripción completa

Detalles Bibliográficos
Autores principales: Hoare, Joseph I., Osmani, Bleona, O’Sullivan, Emily A., Browne, Ashley, Campbell, Nicola, Metcalf, Stephen, Nicolini, Francesco, Saxena, Jayeta, Martin, Sarah A., Lockley, Michelle
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8813932/
https://www.ncbi.nlm.nih.gov/pubmed/35115660
http://dx.doi.org/10.1038/s42003-022-03041-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8813932/
https://www.ncbi.nlm.nih.gov/pubmed/35115660
http://dx.doi.org/10.1038/s42003-022-03041-4

Ejemplares similares